Search Results for: -trf7pw.html

2024-ASCO-Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.

Publications /

2024-ASCO-Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study. Read More »

Actuate Therapeutics Files Registration Statement for Initial Public Offering

May 28, 2024 07:00 ET CHICAGO and FORT WORTH, Texas, May 28, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (“Actuate”) announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be offered and the price

Actuate Therapeutics Files Registration Statement for Initial Public Offering Read More »

Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting

April 08, 2024 08:00 ET CHICAGO and FORT WORTH, Texas, April 08, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today two poster presentations from scientific collaborators at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, California. The abstracts are

Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting Read More »